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Using the existing reverse genetics system developed for the subgroup A respiratory syncytial virus (RSV), a chimeric virus
(designated rA-GBFB) that expresses subgroup B-specific antigens was constructed by replacing the G and F genes of the
A2 strain with those of the 9320 strain of subgroup B RSV. rA-GBFB grew well in tissue culture, but it was attenuated in the
respiratory tracts of cotton rats and African green monkeys. To further attenuate this chimeric RSV, the M2-2 open reading
frame was removed from rA-GBFB. rA-GBFBDM2-2 was highly attenuated in replication in the respiratory tracts of the infected
monkeys, but it provided complete protection against wild-type subgroup B RSV challenge following two doses of infection.
In this study, rA2DM2-2 (a recombinant A2 RSV that lacks the M2-2 gene) was also evaluated in African green monkeys. The
replication of rA2DM2-2 was highly restricted in both the upper and lower respiratory tracts of the infected monkeys and it
induced titers of serum anti-RSV neutralizing antibody that were slightly lower than those induced by wild-type rA2. When
rA2DM2-2-infected monkeys were challenged with wild-type A2 virus, the replication of the challenge virus was reduced by
approximately 100-fold in the upper respiratory tract and 45,000-fold in the lower respiratory tracts. rA2DM2-2 and
rA-GBFBDM2-2 could represent a bivalent RSV vaccine composition for protection against multiple strains from the two RSV
subgroups. © 2001 Academic PressKey Words: recombinant respiratory syncytial virus; RSV vaccines; chimeric RSV; M2-2 deletion mutants; cotton rats;
African green monkeys.
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2INTRODUCTION
Respiratory syncytial virus (RSV) is the leading cause
of serious viral respiratory infection in infants and chil-
dren worldwide. Despite decades of investigation, no
safe and effective vaccines are available to prevent dis-
eases caused by RSV infection. A number of live atten-
uated RSV candidate vaccines, generated by cold pas-
sage and/or chemical mutagenesis, have been evalu-
ated in animals and humans (Crowe et al., 1996a;
Friedewald et al., 1968; Gharpure et al., 1969; Hsu et al.,
1995; Kim et al., 1971; Richardson et al., 1977). These
revious vaccine candidates have been inadequately
ttenuated and in some circumstances genetically un-
table, rendering them unsafe for young children (Hodes
t al., 1974; Kim et al., 1973; Wright et al., 1976, 2000).
ecently, using the reverse genetics system developed
or RSV (Collins et al., 1995; Jin et al., 1998), a large panel
f cDNA-derived attenuated RSV have been obtained
reviewed by Collins et al., 1999). A number of these
ttenuated RSV strains are currently being evaluated for
se as vaccines.
RSV is an enveloped virus and contains a single-
tranded, negative-sense RNA genome of 15,222 nucle-
1 e
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59tides (nt). Ten subgenomic mRNAs are encoded by the
iral genome and are translated into 11 proteins: the
ucleoprotein (N), the phosphoprotein (P), the major
olymerase protein (L), the matrix protein (M), the glyco-
rotein (G), the fusion protein (F), two nonstructural pro-
eins (NS1 and NS2), the small hydrophobic protein (SH),
nd the M2-1 and M2-2 proteins.
The G and F proteins are the major RSV surface
ntigens that elicit neutralizing antibodies in vivo. Two
ntigenically diverse RSV subgroups (A and B) have
een distinguished on the basis of antigenic and se-
uence divergence. Within either subgroup, the G and F
roteins exhibit high degrees of antigenic similarity.
owever, between subgroups, extensive differences are
bserved for the G protein. The antigenic diversity for the
protein between the two subgroups can be as great as
5% (Johnson et al., 1987b). The F glycoprotein is rela-
ively more conserved between the two subgroups. Al-
hough there is 91% identity between the amino acid
equences of the subgroup A and B F protein, the anti-
enic diversity can differ by as much as 50% (Johnson et
l., 1987a). This antigenic diversity enables both sub-
roups to circulate in a community at the same time
Reviewed by McIntosh and Chanock, 1990; Sullender,
000). Although infection with subgroup A or B RSV in
xperimental animals induces a high level of resistance
gainst replication of homologous or heterologous sub-
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Copyright © 2001 by Academic Press
All rights of reproduction in any form reserved.
r
n
f
o
2
c
c
v
C
i
c
b
a
G
n
s
m
u
t
r
s
r
o
sites.
interge
60 CHENG ET AL.group RSV, infection with attenuated RSV induced better
protection against homotypic virus than heterotypic RSV
(Crowe et al., 1997a). Recent studies of a RSV vaccine in
young infants have shown that infants develop dominant
immune response against the RSV G protein than the F
protein (Wright et al., 2000). All these available data
suggest that prevention of serious RSV diseases through
vaccination would require bivalent vaccines containing
antigenic components from both subgroups.
Previously, we described a reverse genetics system to
generate recombinant RSV from cDNA (Jin et al., 1998)
and have used this technology to attenuate subgroup A
RSV (Jin et al., 2000a,b). To expedite the development of
an attenuated subgroup B RSV vaccine, we used the
infectious cDNA developed for the A2 strain to express
heterologous subgroup B specific antigens. The con-
struction of a chimeric RSV that expressed an additional
G protein from a subgroup B virus in a recombinant A2
virus was described earlier (Jin et al., 1998). Here we
describe a recombinant chimeric RSV, designated rA-
GBFB, in which the G and F genes of subgroup A were
eplaced with those of subgroup B. This virus is desig-
ated rA-GBFB. In addition, the M2-2 gene was removed
from rA-GBFB, designated rA-GBFBDM2-2, and this virus
was shown to be more attenuated than rA-GBFB.
African green monkeys (AGM) were evaluated as a
nonhuman primate model for assessing the attenuation,
immunogenicity, and protective efficacy of RSV vaccine
candidates. We showed that rA2 replicated to high titers
in both the upper and the lower respiratory tracts of
AGM, whereas rA2DM2-2, rA-GBFB, and rA-GBFBDM2-2
replicated poorly in the respiratory tracts of monkeys.
However, they all induced sufficient immunity to protect
animals from experimental challenge.
RESULTS
Construction of cDNA and recovery of RSV A/B
chimeric virus
Previously, we constructed an infectious antigenomic
cDNA encoding wt RSV strain A2 and its derivative bear-
ing a deletion of the M2-2 gene. Here, these cDNAs were
modified by replacing the G and F genes of the A2 strain
FIG. 1. Insertion of the G and F genes of RSV 9320 strain into recom
using primers that contained the introduced BamHI restriction enzyme
into the BglII restriction sites that were created in the SH-G and F-M2with those of the subgroup B RSV 9320 strain to produce
chimeric viruses expressing RSV subgroup B antigens.
RThe gene-start and gene-end sequences are very con-
served between the two RSV subgroups. Therefore, the
complete G and F genes of 9320 including their own
gene-start and gene-end signals were transferred to the
A2 cDNA backbone (Fig. 1). The cDNA encoding the G
and F genes of 9320 was obtained by RT/PCR and
confirmed by sequence analysis. The constructed chi-
meric cDNA was designated pRSVA-GBFB. pRSVA-
GBFBDM2-2 was constructed by deleting the M2-2 gene
rom pRSVA-GBFB. The M2 gene containing the deletion
f the M2-2 open reading frame from rA2DM2-2 (Jin et al.,
000a) was introduced into pRSVA-GBFB through the
unique MscI and BamHI restriction enzyme sites. Both
chimeric viruses (rA-GBFB and rA-GBFBDM2-2) were re-
overed from cDNA using the previously described res-
ue system (Jin et al., 1998). The recovered recombinant
iruses were plaque-purified and amplified in Vero cells.
haracterization of the recombinant chimeric viruses
n vitro
Expression of the subgroup specific proteins by the
himeric viruses was analyzed by Northern and Western
lotting. Using strain-specific probes, 9320-specific G
nd F mRNAs were detected in cells infected with rA-
BFB and rA-GBFBDM2-2 (Fig. 2A). The M2-2 gene was
ot detected in cells infected with rA-GBFBDM2-2 (lane 5),
confirming that the M2-2 gene was deleted from this
chimeric virus. The 9320 strain-specific protein expres-
sion of the two chimeric viruses was also compared with
that of rA2, rA2DM2-2, and wild-type 9320 (Fig. 2B). The
F1 protein of rA-GBFB and rA-GBFBDM2-2 showed the
ame rate of migration mobility as that of 9320; both
igrated faster than that of A2. Western blotting analysis
sing strain-specific monoclonal antibodies confirmed
hat the G protein of subgroup B was expressed by
A-GBFB and rA-GBFBDM2-2 (Fig. 2B). Immunoprecipita-
tion using a polyclonal antibody specific to the M2-2
protein further confirmed the ablation of the M2-2 gene in
rA2DM2-2 and rA-GBFBDM2-2. The M2-2 protein of RSV
train 9320 was not detected by the polyclonal antiserum
aised against the M2-2 protein of strain A2 as there is
nly 62% homology between the M2-2 proteins of the two
A2 strain. The G and F genes of RSV 9320 were amplified by RT/PCR
The DNA cassette containing the G and F genes of 9320 was cloned
nic regions of the A2 strain.binantSV subgroups.
Replication of chimeric viruses, rA-GBFB and rA-
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61CHIMERIC SUBGROUP A RESPIRATORY SYNCYTIAL VIRUSGBFBDM2-2, was compared to rA2 and rA2DM2-2 in both
the HEp-2 and the Vero cells (Fig. 3). In Vero cells,
infected at an m.o.i. of 0.1, both rA-GBFB and rA-
BFBDM2-2 reached peak titers similar to that seen with
ild-type rA2 and rA2DM2-2, respectively. At a lower
.o.i. of 0.01, the peak titer of rA-GBFB was slightly re-
uced compared to rA2; the level of replication of rA-
BFBDM2-2 was reduced by about 10-fold compared to
A-GBFB. In HEp-2 cells, at m.o.i. of 0.1, rA-GBFB showed a
slightly lower peak titer compared to wt A2, whereas the
replication of rA-GBFBDM2-2 was reduced by about 100-
fold. At m.o.i. of 0.01, the peak titer of rA-GBFB was
reduced by about 10-fold compared to rA2 and the peak
titer of rA-GBFBDM2-2 was reduced by 100-fold. There-
ore, similar to that observed for rA2DM2-2, rA-
BFBDM2-2 also exhibited restricted replication in HEp-2
FIG. 2. Strain-specific expression of the chimeric RSV rA-GBFB and
rA-GBFBDM2-2. (A) Viral RNA expression. Total cellular RNA were ex-
tracted from virus-infected Vero cells and the Northern blots were
hybridized with probes specific to the G or F gene of either subgroup
A or subgroup B RSV. The M2-2 gene expression was examined by
using a riboprobe specific to the M2-2 open reading frame. (B) Viral
protein expression. The infected Vero cells were labeled with 35S-
ethionine and 35S-cysteine and the cell lysate immunoprecipitated
ith anti-RSV polyclonal antibody or anti-M2-2 antibody. To detect the
protein expression, the infected cell extracts were subjected to
estern blotting using subgroup-specific monoclonal antibody against
he G protein. Both rA-GBFB and rA-GBFBDM2-2 expressed the sub-
group B-specific G and F proteins and retained normal expression of
the other genes derived from the subgroup A2 backbone. No M2-2
protein was expressed in rA2DM2-2 and rA-GBFBDM2-2 infected cells.
The M2-2 protein of strain 9320 was not recognized by the polyclonal
serum raised against the M2-2 protein of strain A2. Lane 1: rA2; lane 2:
rA2DM2-2; lane 3: 9320; lane 4: rA-GBFB; lane 5: rA-GBFBDM2-2.ells, whereas its replication in Vero cells was less
mpaired.
m
aeplication of chimeric RSV in cotton rats
Cotton rats are susceptible to both subgroup A and
ubgroup B RSV infection. The levels of replication of
A-GBFB and rA-GBFBDM2-2 in the nasal turbinates and
ungs of cotton rats were compared with rA2, rA2DM2-2,
nd wild-type 9320 (Table 1). The replication of rA-GBFB
was below the limit of detection by plaque assay in the
nasal turbinates; its replication in lung tissue was re-
duced by about 3.6 log10 compared to wild-type 9320 and
by about 2.0 log10 relative to rA2. The replication of
rA2DM2-2 was not detected in the nasal turbinates and
was 1.6 log lower in the lung compared to rA2. Removal
of M2-2 from rA-GBFB further attenuated the chimeric
virus. No virus replication was detected in either the
nasal turbinates or the lungs of cotton rats infected with
rA-GBFBDM2-2.
Although rA-GBFB and rA-GBFBDM2-2 were attenuated
n cotton rats, both chimeric viruses induced sufficient
mmunity to protect the animals from homologous and
eterologous RSV challenge (Table 1). rA-GBFBDM2-2
induced complete protection against subgroup B RSV
challenge, but its protection against the heterotypic sub-
group A RSV challenge was incomplete in cotton rats. A
low level of A2 challenge virus replication was detected
in the nasal turbinates of cotton rats previously infected
with rA-GBFBDM2-2. The level of serum anti-RSV neutral-
zing antibody induced by rA-GBFB was 2.85-fold lower
relative to that induced by wild-type 9320. Serum anti-
RSV neutralizing antibody induced by rA-GBFBDM2-2 was
approximately fourfold lower compared to that induced
by 9320 and 1.5-fold lower than that of rA-GBFB. By com-
parison, the level of serum anti-RSV neutralizing antibody
induced by rA2DM2-2 was similarly reduced by approx-
imately twofold compared to that of rA2.
Replication of wt RSV and rA2DM2-2 in AGM
To investigate RSV attenuation and immunogenicity in
primates, replication of recombinant RSV was further
studied in AGM. Study A examined the replication of
recombinant A2 and wild-type A2 virus in the respiratory
tracts of AGM. RSV seronegative AGM were infected with
5.5 log10 pfu of rA2 or wt A2 intranasally and intratrache-
lly and virus shedding was monitored over a period of
2 days in both the upper and the lower respiratory
racts. As shown in Table 2, rA2 replicated well in both
he upper and the lower respiratory tracts of AGM. rA2
eached a peak titer of 4.18 and 4.28 log10 pfu/ml at each
ite, respectively, and shed virus over the same length of
ime as the wild-type A2 virus (Table 2, study A), though
he peak titer of rA2 in the respiratory tracts of AGM was
lightly lower than that obtained for wild-type A2 virus.
aving confirmed a high level of replication of rA2 in
GM, rA2DM2-2 was evaluated for its attenuation, im-
unogenicity, and protective efficacy in AGM. In a sep-
rate study (study B, Table 2), rA2DM2-2 showed a
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62 CHENG ET AL.greatly reduced level of replication in both the nasophar-
ynx and the trachea compared to rA2. Its peak titer in
nasopharynx was reduced by 3.1 log10, whereas the peak
iter in the trachea was reduced by 3.25 log10 compared
o rA2. Despite the much lower level of replication in the
espiratory tracts, rA2DM2-2 induced a significant level
f serum anti-RSV neutralizing antibody. The antibody
iter induced by rA2DM2-2 was about fourfold lower than
hat induced by rA2 at 3 weeks postinfection (Table 3).
hen challenged with wild-type A2 virus, rA2DM2-2 pro-
ided partial protection against wild-type RSV replication
n the upper respiratory tract and much greater protec-
ion in the lower respiratory tract of immunized monkeys.
onkeys previously infected with rA2 were fully pro-
ected against wt A2 virus replication in both the upper
nd the lower respiratory tracts (Table 3). Although
A2DM2-2 did not provide complete protection in the
espiratory tracts of immunized monkeys, it reduced vi-
FIG. 3. Growth kinetics of the chimeric viruses in Hep-2 and Vero c
f either 0.1 or 0.01. At 24 h intervals, the infected culture supernatantus shedding by 5 days. Two weeks after challenge, the
evel of serum anti-RSV neutralizing antibody fromA2DM2-2 infected monkeys approached that induced by
A2.
eplication of chimeric RSV and wild-type 9320 in
GM
We next compared the level of replication of chimeric
A-GBFB with that of wild-type 9320. RSV seronegative
GM were inoculated with 5.5 log10 pfu of rA-GBFB or
9320 by intranasal and intratracheal instillation. The
throat swab and tracheal lavage samples were collected
over 12 days for virus quantitation. 9320 replicated to a
level similar to that of wild-type A2 virus (Table 2). The
peak titer of rA-GBFB at both sites of the respiratory tracts
of the infected monkeys was about 1000-fold reduced
compared to that of 9320. Animals infected with rA-GBFB
shed virus for a shorter period of time than those infected
with 9320. Despite its significantly attenuated replication,
p-2 or Vero cells were infected with viruses in duplicates at an m.o.i.
harvested and virus titers determined by plaque assay in Vero cells.rA-GBFB provided complete protection when challenged
with wild-type 9320. No challenge virus was detected in
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63CHIMERIC SUBGROUP A RESPIRATORY SYNCYTIAL VIRUSeither the upper or the lower respiratory tracts of the
monkeys previously immunized with rA-GBFB (Table 3).
Consistent with the level of protection seen in monkeys
immunized with rA-GBFB, the level of serum anti-RSV
eutralizing antibody from these monkeys was similar to
hat observed for wild-type 9320-infected animals.
rA-GBFBDM2-2 was evaluated in AGM in a separate
tudy (study C). The replication of rA-GBFBDM2-2 was not
detected in the upper respiratory tracts and a very low
level of virus replication was detected in the lower res-
piratory tracts of the infected monkeys (Table 2). Since
rA-GBFBDM2-2 appeared to be more attenuated than
A-GBFB and rA2-DM2-2, an additional boosting dose
was administered 4 weeks later. The boosting infection
greatly augmented immune response and provided com-
plete protection against wild-type 9320 RSV challenge.
The level of serum anti-RSV neutralizing antibody in-
T
Replication, Immunogenicity, and Protection of Recom
Respiratory Tr
Virusa
Virus titer b
(mean log10pfu/g 6 SE)
Neutralizin
titer (me
reciprocalNT Lung
rA2 3.9 6 0.13 3.57 6 0.07 10.0
rA2DM2-2 ,1.4 2.02 6 0.12 9.0
ontrol ,1.4 ,1.4 ,3.3
320 2.8 6 0.57 5.6 6 0.05 10.64
A-GBFB ,1.4 1.94 6 0.31 9.13
A-GBFBDM2-2 ,1.4 ,1.4 8.57
a Cotton rats were administered with 5.5 log10PFU of virus intranasa
b Virus titers from the nasal turbinates (NT) and lung tissues were d
c Serum RSV neutralizing antibody titers were determined by a com
d On day 21 of virus infection, cotton rats in groups of six were cha
turbinates (NT) and lung tissues were determined by plaque assay.
e ND, not determined.
T
Replication of Recombinant RSV in the Upper an
Virusa AGM number
Virus she
(days
wt A2 4 (Study A) 8
rA2 4 (Study A) 8
rA2 4 (Study B) 9
rA2DM2-2 4 (Study B) 4
9320 4 (Study B) 9
rA-GBFB 4 (Study B) 4
rA-GBFBDM2-2 4 (Study C) 3
a African green monkeys were administered with 5.5 log10PFU of
ollected daily for 12 days, and tracheal-lavage samples were collected on d
b Virus titers were determined in the nasopharyngeal swab and tracheal-laduced by rA-GBFBDM2-2 was about fourfold lower than
hat induced by rA-GBFB. However, after a second dose of
boosting infection, the level of serum neutralizing anti-
body was increased by about eightfold and it was further
augmented by an additional twofold following subse-
quent wild-type RSV infections.
DISCUSSION
In an attempt to develop live attenuated RSV vaccine,
we are using a recently developed reverse genetics
system to attenuate RSV by introducing various muta-
tions into the RSV genome. This approach has generated
a number of attenuated subgroup A recombinant RSV by
different groups (Jin et al., 2000a,b; Teng and Collins,
1999; Teng et al., 2000; Bermingham and Collins, 1999;
Whitehead et al., 1999a,b). To expedite vaccine develop-
RSV against wt RSV Infection in the Upper and Lower
f Cotton Rats
Titer of challenge virus (mean log10pfu/g 6 SE)
d
A2 9320
NT Lung NT Lung
,1.4 ,1.4 NDe ND
,1.4 ,1.4 ND ND
4.2 6 0.14 6.0 6 0.06 2.3 6 0.53 5.2 6 0.01
,1.4 ,1.4 ,1.4 ,1.4
,1.4 ,1.4 ,1.4 ,1.4
1.2 6 0.65 ,1.4 ,1.4 ,1.4
er light anesthesia on day 0 and sacrificed on day 4.
ned by plaque assay.
t-enhanced 50% plaque reduction assay with wt A2 or 9320.
with wt A2 or wt 9320 and the challenge virus titers from the nasal
r Respiratory Tracts of African Green Monkeys
Virus peak titer (Mean log10pfu 6 SE)
b
Nasopharyngeal swab Tracheal lavage
4.67 6 0.17 4.97 6 0.04
4.18 6 0.18 4.28 6 0.27
3.44 6 0.27 3.91 6 0.18
0.33 6 0.26 0.66 6 0.40
4.51 6 0.18 4.36 6 0.45
1.50 6 0.42 1.77 6 0.25
,0.7 0.25 6 0.25
tranasally and intratracheally. Nasopharyngeal swab samples wereABLE 1
binant
acts o
g Ab
an
log2)
c
lly und
etermi
plemen
llengedABLE 2
d Lowe
dding
)
virus in
ays 3, 5, 7, and 10.
vage by plaque assay and only the peak titers are shown.
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64 CHENG ET AL.ment for subgroup B RSV, we used recombinant A2 virus
as a vector to express subgroup B RSV surface antigens.
The chimeric virus should elicit a balanced immune
response and provide protection against subgroup B
RSV infection. Previously, we described a chimeric virus,
A2(B-G), that expressed two G proteins, one derived from
A2 strain and the other derived from 9320 strain (Jin et al.,
998). A2(B-G) provided complete protection against sub-
equent wild-type RSV A and B strains infection in cotton
ats. While this chimeric virus retained both G genes of
wo subgroups during passage in tissue culture, frame-
hift mutations have been detected at oligo(A) tracts of
ne or the other subgroup G gene on separate occa-
ions during in vitro passages. As an alternative ap-
proach to expressing RSV subgroup B antigens, we con-
structed a different chimeric virus in which the G and F
genes of the A2 strain were completely replaced by the
G and F genes of the 9320 strain. The chimeric RSV was
then further attenuated using a strategy developed for
attenuating the A2 virus.
The recovered chimeric RSV (rA-GBFB) replicated effi-
ciently in Vero cells, but its growth in HEp-2 cells was
reduced by 5- to 10-fold relative to rA2. rA-GBFB was
ttenuated in both the upper and the lower respiratory
racts of cotton rats. To determine whether the attenua-
ion of rA-GBFB was host specific, this chimeric virus was
further evaluated in AGM that are genetically more
closely related to humans than rodents. RSV infection in
AGM is less well characterized and there is a wide range
in the reported peak titer (Crowe et al., 1996b; Kakuk et
al., 1993). Therefore, we first tested RSV infection in AGM
T
Evaluation of Recombinant RSV for Their Levels of Immunogenicity
Virus
Challenge
virusa
Virus peak titer (M
Nasopharyngeal swab
rA2 A2 ,0.7
rA2DM2-2 A2 2.64 6 0.07
None A2 4.67 6 0.17
9320 9320 ,0.7
rA-GBFB 9320 ,0.7
rA-GBFBDM2-2
d 9320 ,0.7
None 9320 4.51 6 0.18
a African green monkeys were administered with 5.5 log10PFU of vir
ith wt A2 or wt 9320 at a dose of 5.5 log10PFU intranasally and intra
b Nasopharyngeal swab samples were collected daily for 10 days, an
virus titers were determined by plaque assay. Only the peak titers are
c Serum RSV neutralizing antibody titers from monkeys infected wi
challenge (day 42) were determined by a complement-enhanced 50%
monkeys infected with 9320, rA-GBFB, and rA-GBFBDM2-2 were determ
d An additional boosting dose was administered; shown here is postb
(day 70) was 9.75 log2.using wild-type viruses. We showed that both subgroup
A and subgroup B RSV replicated equally well in AGMand virus titers recovered from the upper and lower
respiratory tracts of AGM approached those observed in
infected chimpanzees (Crowe et al., 1994). When rA-GBFB
was evaluated in AGM, it showed a mean peak titer
reduction of 3.0 log10 in the upper respiratory tract and a
reduction of 2.59 log10 in the lower respiratory tract.
The level of attenuation of rA-GBFB in AGM was con-
istent with what we observed in cotton rats. However,
his result was somewhat different from that reported for
recently described chimeric RSV in which the G and F
enes of A2 were replaced with those of RSV B1 strain
rAB1) (Whitehead et al., 1999b). Though rAB1 and rA-
BFB are similarly attenuated in cotton rats, rAB1 was not
ttenuated in chimpanzees. In contrast to rA-GBFB, rAB1
replicated better than wt RSV B1 in both the upper and
the lower respiratory tracts of chimpanzees (Whitehead
et al., 1999b). Part of this discrepancy may be explained
by the semipermissiveness of chimpanzees to wild-type
subgroup B RSV infection. However, there exists the
possibility that rA-GBFB is more attenuated than rAB1
because of differences in the subgroup B strain surface
antigens or constellation effects when these antigens
are introduced into an A2 background. Chimerization of
surface antigens resulting in an attenuated virus has
been reported for several paramyxoviruses. A chimeric
measles virus with the HN and F proteins replaced by
the G protein of VSV was highly restricted in replication
in vitro (Spielhofer et al., 1998). A chimeric Rinderpest
virus in which the F and H proteins were replaced by the
heterologous surface proteins of a closely related peste-
des-petits-ruminants virus was attenuated in vitro, as
icacy against Wild Type Challenge Virus in African Green Monkeys
10pfu 6 SE)
b
Neutralizing Ab titer
(Mean reciprocal log2)
c
Tracheal lavage Day 0 Day 28 Day 42
,0.7 ,3.3 9.7 10.5
0.46 6 0.47 ,3.3 7.7 9.25
4.97 6 0.04 ,3.3 ,3.3 10.5
,0.7 ,3.3 7.0 10.0
,0.7 ,3.3 7.75 10.5
,0.7 ,3.3 5.5 8.75d
4.36 6 0.35 ,3.3 ,3.3 10.0
nasally and intratracheally and on day 28; monkeys were challenged
lly.
eal-lavage samples were collected on days 3, 5, 7, and 10. Challenge
.
and rA2DM2-2 before challenge infection (day 28) and 14 days post
e reduction assay with wt A2. The neutralizing antibody titers from
y microneutralization assay (Cheng et al., manuscript in preparation).
neutralizing antibody titer at day 56. The antibody titer after challengeABLE 3
and Eff
ean log
us intra
trachea
d trach
shown
th rA2
plaqu
ined bindicated by slow virus growth and low virus yield (Das et
al., 2000). Most recently, it was reported that the PIV3-
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65CHIMERIC SUBGROUP A RESPIRATORY SYNCYTIAL VIRUSPIV2 chimeric virus, in which the F and HN genes of PIV3
were replaced by those of PIV2, was not attenuated in
vitro, but it was highly attenuated in hamsters, AGM, and
chimpanzees (Tao et al., 2000). On the other hand, the
chimeric PIV3-PIV1 was not attenuated in vivo (Tao et al.,
1998, 1999). Thus, it appears that chimerization of differ-
ent heterologous proteins can result in different pheno-
types. Though attenuated in AGM, rA-GBFB induced sig-
ificant levels of anti-RSV neutralizing antibody and pro-
ided complete protection against subsequent challenge
ith wild-type subgroup B RSV.
We previously reported that the recombinant A2 RSV
acking the M2-2 gene is attenuated in mice and cotton
ats. In this study, we evaluated rA2DM2-2 for its atten-
ation, immunogenicity, and protection against wild-type
SV challenge in AGM. We showed that rA2DM2-2 was
ttenuated in the respiratory tracts of AGM and following
hallenge, much reduced replication of wild-type RSV
as observed in animals previously infected with
A2DM2-2. The protection was higher in the lower respi-
atory tract than the upper respiratory tract. The level of
eplication and protection observed for rA2DM2-2 in
GM is very similar to that reported in a chimpanzee
tudy for a similar recombinant RSV that had the M2-2
rotein expression silenced (Bermingham and Collins,
999; Teng et al., 2000). rA2DM2-2 may prove to be more
ttenuated in humans than a previously tested vaccine
andidate cpts248/404 (Teng et al., 2000). cpts248/404
as neither sufficiently attenuated nor genetically stable
n naive infants (Crowe et al., 1994; Wright et al., 2000).
he serum anti-RSV neutralizing antibody titer induced
y rA2DM2-2 was slightly lower than that induced by the
ild-type RSV infection. However, the augmentation of
eutralizing antibody titer after the challenge suggests
hat the immunogenicity of rA2DM2-2 could be enhanced
y repeat administrations.
Since rA2DM2-2 exhibits many of the desired features
n a live attenuated vaccine, we considered the deletion
f the M2-2 gene an appropriate way to further attenuate
he chimeric rA-GBFB. In vitro studies indicated that rA-
GBFBDM2-2 had phenotypes similar to rA2DM2-2, exhib-
ting increased syncytial formation, reduced growth in
Ep-2 cells, and unbalanced RNA transcription to repli-
ation. rA-GBFBDM2-2 was more attenuated than rA-GBFB
and rA2DM2-2 in both cotton rats and AGM. This atten-
uated replication in the host led to its reduced immuno-
genicity. Thus, although rA-GBFB provided complete pro-
ection to both subgroup A and subgroup B RSV chal-
enge, A-GBFBDM2-2 provided lower protection to
subgroup A virus infection than to subgroup B strain
infection in cotton rats. A very low level of serum anti-
RSV neutralizing antibody was detected in monkeys in-
fected with rA-GBFBDM2-2. The second dose administra-
tion of A-GBFBDM2-2 greatly augmented antibody re-
sponse and provided complete protection against
subsequent experimental challenge in AGM. Our dataimplied that a live attenuated RSV vaccine containing
components from both subgroups need to be adminis-
tered in multiple doses to achieve a higher level of
durable immunity. rA-GBFBDM2-2, in combination with
rA2DM2-2, may represent suitable vaccines for protect-
ing against both subgroup A and subgroup B RSV infec-
tions.
MATERIALS AND METHODS
Cells and viruses
Monolayer cultures of HEp-2 and Vero cells (obtained
from American Type Culture Collections, ATCC) were
maintained in minimal essential medium (MEM) contain-
ing 5% fetal bovine serum (FBS). Wild-type RSV strains,
A2 and 9320, were obtained from ATCC and grown in
Vero cells. Modified vaccinia virus Ankara (MVA-T7) ex-
pressing bacteriophage T7 RNA polymerase was pro-
vided by Dr. Bernard Moss and grown in CEK cells.
Construction of chimeric cDNA clone
The wild-type RSV strain 9320, originally isolated in
Massachusetts in 1977 and classified as subgroup B
RSV (Hierholzer and Hirsch, 1979), was used in this
study. The 9320 RSV was grown in Vero cells and the
viral RNA was extracted from infected cell culture super-
natant. A cDNA fragment containing the G and F genes
of RSV 9320 was obtained by RT/PCR using the following
primers: ATCAGGATCCACAATAACATTGGGGCAAATGC-
AACC and CTGGCATTCGGATCCGTTTTATGTAACTAT-
GAGTTG (the BamHI sites engineered for cloning are in
italics and 9320 specific sequences are underlined).
BamHI restriction enzyme sites were introduced up-
stream of the gene start sequence of G and downstream
of the gene end sequence of F. The PCR product was first
introduced into the T/A cloning vector (Invitrogen) and
the sequences were confirmed by DNA sequencing. The
BamHI restriction fragment containing the G and F gene
cassette of 9320 was then transferred into a RSV cDNA
subclone pRSV(R/H) that contained RSV sequences from
nt 4326 to nt 9721 through the introduced BglII sites at nt
4655 (upstream of the gene start signal of G) and at nt
7552 (downstream of the gene end signal of F). Introduc-
tion of these two BglII sites were made by PCR mutagen-
esis using the QuickChange mutagenesis kit (Strate-
gene, La Jolla, CA). BamHI and BglII restriction enzyme
sites have compatible ends but ligation obliterates both
restriction sites. The XhoI (nt 4477) to BamHI (nt 8498)
restriction fragment containing the G and F genes of
9320 was examined by sequencing analysis and then
shuttled into the infectious RSV antigenomic cDNA clone
pRSVC4G (Jin et al., 1998). The chimeric antigenomic
cDNA was designated pRSV-GBFB. To delete the M2-2
gene from pRSV-GBFB, the Msc I (nt 7692) to BamHI (nt
8498) fragment from rA2DM2-2 which contained the
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66 CHENG ET AL.M2-2 deletion (Jin et al., 2000a) was introduced into
pRSV-GBFB. The chimeric cDNA clone that lacks the
2-2 gene was designated pRSV-GBFBDM2-2.
ecovery of recombinant RSV
Recovery of recombinant RSV from cDNA was de-
cribed previously (Jin et al., 1998). Briefly, HEp-2 cells in
ix-well plates at 80% confluence were infected with
VA at an m.o.i. of 5 pfu/cell for 1 h and then were
ransfected with full-length antigenomic plasmids (pRSV-
BFB or pRSV-GBFBDM2-2), together with plasmids ex-
pressing the RSV N, P, and L proteins using LipofecTACE
reagent (Life Technologies, Gaithersburg, MD). After in-
cubating the transfected cells at 35°C for 3 days, the
culture supernatants were passaged in Vero cells for 6
days to amplify rescued virus. The recovered recombi-
nant viruses were biologically cloned by three succes-
sive plaque purifications and further amplified in Vero
cells. Virus recovered from pRSV-GBFB-transfected cells
as designated rA-GBFB and that from pRSV-GBFBDM2-2
transfected cells was designated rA-GBFBDM2-2. Virus
iter was determined by plaque assay and plaques were
numerated by immunostaining using polyclonal anti-
SV A2 serum (Biogenesis, Sandown, NH).
irus characterization
The expression of viral RNA for each recovered chi-
eric RSV was analyzed by Northern blotting. Total cel-
ular RNA was extracted from virus-infected cells at 48 h
ostinfection. The RNA blot was hybridized with a
g-[32P]ATP-labeled oligonucleotide probe specific for the
gene of 9320 (GAGGTGAGGTACAATGCATTAATAG-
AAGATGGAGGAAGA) or a g-[32P]ATP-labeled probe
pecific for the F gene of A2 (CAGAAGCAAAACAAAAT-
TGACTGCAGTGAGGATTGTGGT). To detect the G
RNA of the chimeric viruses, RNA blots were hybrid-
zed with a 190-nt riboprobe specific to the G gene of
320 or a 130-nt riboprobe specific to the G gene of A2.
oth riboprobes were labeled with a-[32P]-CTP. Hybrid-
zation was performed at 65°C in Express Hyb solution
Clontech, Palo Alto, CA) overnight. Membranes were
ashed at 65°C under stringent conditions and exposed
o film.
Viral specific proteins from infected cells were ana-
yzed by immunoprecipitation of the infected cell extracts
r by Western blotting. To immunoprecipitate viral pro-
eins, Vero cells were infected with virus at an m.o.i. of 1.0
nd labeled with 35S-promix (100 mCi/ml 35S-Cys and
35S-Met; Amersham, Arlington Heights, IL) from 14 to 18 h
ostinfection. The labeled cell monolayers were lysed
ith RIPA buffer and the polypeptides immunoprecipi-
ated by polyclonal goat anti-RSV A2 serum (Biogenesis)
r by a polyclonal antibody against the M2-2 protein (Jin
t al., 2000a). Immunoprecipitated polypeptides were
lectrophoresed on SDS–PAGE and detected by autora-iography. For Western blotting analysis, virus-infected
ero cells were lysed in protein lysis buffer and the
roteins were separated on 12% SDS–PAGE. The pro-
eins were transferred to a nylon membrane and immu-
oblotting was performed as described (Jin et al., 1997),
sing a monoclonal antibody recognizing the G protein of
train 9320 or a monoclonal antibody against the G
rotein of A2 (Storch and Park, 1987).
Growth of chimeric RSV in vitro was compared with
ild-type recombinant A2 (rA2) and rA2DM2-2. Growth-
ycle analysis was performed in both HEp-2 and Vero
ells. Cells grown in 6-cm dishes were infected with
ach virus at a m.o.i. of 0.01 or 0.1. After 1 h absorption at
oom temperature, the infected cell monolayers were
ashed 3 times with PBS and incubated at 35°C with 4
l of Opti-MEM in an incubator containing 5% CO2. At
arious times postinfection, 200 ml of the culture super-
atant was collected and stored at 270°C for virus
itration. Each aliquot removed was replaced with an
qual amount of fresh medium. Virus titer was deter-
ined by plaque assay in Vero cells on 12-well plates
sing an overlay of 1% methylcellulose and 13 L15
edium containing 2% FBS.
irus replication in cotton rats
Virus replication in vivo was determined in respiratory
athogen-free Sigmodon Hispidus cotton rats. Cotton
ats in groups of 12 or 18 were inoculated intranasally
nder light methoxyflurane anesthesia with 105.5 pfu of
irus per animal in a 0.1-ml inoculum. On day 4 postin-
culation, six animals were sacrificed by CO2 asphyxia-
tion and their nasal turbinates and lungs were harvested
separately. Tissues were homogenized and virus titers
determined by plaque assay in Vero cells. Three weeks
later, the remaining six animals were anesthetized, their
serum samples were collected, and a challenge inocu-
lation of 106 pfu of biologically derived wild-type RSV
strain A2 or 9320 administered intranasally. To investi-
gate the cross-protection of the chimeric viruses to het-
erologous RSV, six additional animals infected with rA-
GBFB or rA-GBFBDM2-2 were also challenged with wt A2
RSV. Four days postchallenge, the animals were sacri-
ficed and both nasal turbinates and lungs were har-
vested, homogenized, and virus titer determined by
plaque assay. Serum neutralizing antibodies against RSV
A2 or 9320 strain were determined by a 50% plaque
reduction assay (Coates et al., 1966).
Virus replication in AGM
Recombinant RSV was evaluated for their replication,
immunogenicity, and protective efficacy in AGM (Cerco-
pithecus aethiops). AGM, obtained from St. Kitts with an
average age of 4.2 years and body weight ranging from
2.2 to 4.3 kg, were used in the first study (study A) to
compare the replication of rA2 with wild-type A2. The
1
n
m
c
a
i
a
b
s
d
a
c
m
r
k
4
w
t
a
C
C
C
D
F
G
H
H
H
J
J
J
J
67CHIMERIC SUBGROUP A RESPIRATORY SYNCYTIAL VIRUSsecond study (study B) used AGM with ages ranging
from 5.3 to 8.4 years and an average body weight of 4.15
kg. None of the monkeys had detectable serum neutral-
izing antibodies for RSV 9320 or A2 (titer , 1:10). Groups
of four monkeys were inoculated with either wild-type A2,
rA2, rA2DM2-2, wild-type 9320, or rA-GBFB by both intra-
nasal and intratracheal route with a dose of 105.5 pfu in a
.0 ml inoculum at each site. Following inoculation, daily
asopharyngeal (NP) swabs were collected from each
onkey for 12 days under Telazol anesthesia and bron-
hoalveolar lavage (BAL) were collected on days 3, 5, 7,
nd 10 postinfection (Kakuk et al., 1993). On day 28
postinfection, serum samples were collected from each
infected monkey and the monkeys were challenged with
either wild-type A2 or 9320 at both the intranasal and the
intratracheal sites with a dose of 105.5 pfu in a 1.0-ml
noculum. Replication of the challenge virus in the upper
nd lower respiratory tracts of monkeys was examined
y quantitation of virus shed in NP and tracheal lavage
pecimens. The NP samples were collected daily for 10
ays and BAL samples were collected on days 3, 5, 7,
nd 10 postchallenge. Fourteen days after wild-type virus
hallenge, serum samples were collected for measure-
ent of RSV neutralizing antibody. rA-GBFBDM2-2 was
evaluated in a separate study (study C). Four week after
infection, a group of four monkeys were administered
with an additional boosting dose of 5.5 log10 pfu of
A-GBFBDM2-2 intranasally and intratracheally and mon-
eys were challenged with 5.5 log10 pfu of wt 9320 virus
weeks after boosting infection. NP and BAL samples
ere collected from rA-GBFBDM2-2-infected monkeys
the same as described for those infected with rA-GBFB.
Serum samples were collected at day 0 (preserum), day
28 (preboosting), day 56 (postboosting), and day 70
(postchallenge). The levels of neutralizing antibody from
monkeys infected with rA2 and rA2DM2-2 were deter-
mined by the 50% plaque reduction assay using wild-
type A2 virus. The levels of neutralizing antibody from
monkeys infected with 9320, rA-GBFB, and rA-GBFBDM2-2
were determined by a microneutralization assay (Cheng
et al., manuscript in preparation). The virus shedding in
he NP and BAL samples were quantitated by plaque
ssay using Vero cells.
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